Pancreatic Cancer Research

ResearcherUniversitair Ziekenhuis LeuvenActive in the last 2 years

Baki Topal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2687-7535; OpenAlex author ID A5061742246. Sources: ClinicalTrials.gov.

Their work

Papers
14 (first author 0, last author 8)
Trials
5 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
33
Papers, trials and grants by year

2009: 1 trial · 2010: 1 trial · 2011: 1 paper · 2012: 3 papers, 1 trial · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper, 1 trial · 2017: none · 2018: none · 2019: none · 2020: 2 papers, 1 trial · 2021: none · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 14

  1. Real-world feasibility and safety of neoadjuvant FOLFIRINOX in pancreatic ductal adenocarcinoma: a retrospective single-center study. Co-author DOI 10.21037/jgo-2026-1-0041↗
  2. Progression-free survival for unresectable non-metastatic locally advanced pancreatic cancer after surgical microwave ablation plus durvalumab and tremelimumab… Last author DOI 10.1038/s43856-025-01186-x↗
  3. Intrinsic temperature increase drives lipid metabolism towards ferroptosis evasion and chemotherapy resistance in pancreatic cancer. Co-author DOI 10.1038/s41467-024-52978-z↗
  4. Survival After Minimally Invasive vs Open Surgery for Pancreatic Adenocarcinoma. Last author DOI 10.1001/jamanetworkopen.2022.48147↗
  5. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2022.100386↗
  6. Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. Co-author DOI 10.1038/s43018-022-00470-2↗
  7. 3D-laparoscopic pancreaticoduodenectomy with superior mesenteric or portal vein resection for pancreatic cancer. Last author DOI 10.1007/s00464-020-07847-3↗
  8. Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer. Co-author DOI 10.1016/j.tranon.2020.01.004↗
  9. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12885-016-2540-6↗
  10. Human pancreatic cancer contains a side population expressing cancer stem cell-associated and prognostic genes. Last author DOI 10.1371/journal.pone.0073968↗
  11. Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. Co-author DOI 10.1186/1471-2407-12-354↗
  12. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery. Last author DOI 10.1186/1471-2407-12-527↗
  13. Molecular markers associated with outcome and metastasis in human pancreatic cancer. Last author DOI 10.1186/1756-9966-31-68↗
  14. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarci… Last author DOI 10.1186/1471-2407-11-47↗

Trials 5

  1. Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer Principal investigator NCT04156087↗
  2. Enhanced Recovery After Minimally Invasive Pancreaticoduodenectomy Principal investigator NCT02671357↗
  3. Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Trial on Standard Open Versus Minimally Inva… Study director NCT01712971↗
  4. Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastroin… Principal investigator NCT01116791↗
  5. Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Pancreaticojejunostomy Study director NCT00830778↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Halit Topal · 5 shared papers, 2020–2026 · strength 1.13
  2. Eric Van Cutsem · 3 shared papers, 2020–2025 · strength 0.53
  3. Jeroen Dekervel · 2 shared papers, 2020–2026 · strength 0.46
  4. Soetkin D’Haens · 1 shared paper, 2026 · strength 0.36
  5. Joachim Geers · 2 shared papers, 2020–2022 · strength 0.34
  6. Johannes V. Swinnen · 2 shared papers, 2016–2024 · strength 0.23
  7. Anke Van den broeck · 4 shared papers, 2012–2016 · strength 0.18
  8. Vincent de Laat · 1 shared paper, 2024 · strength 0.17
  9. Maria Fedorova · 1 shared paper, 2024 · strength 0.17
  10. Jean‐Luc Van Laethem · 1 shared paper, 2022 · strength 0.16
  11. Karen Paula Geboes · 1 shared paper, 2022 · strength 0.16
  12. Frederik Christiaan Berrevoet · 1 shared paper, 2022 · strength 0.16
  13. Geert Roeyen · 1 shared paper, 2022 · strength 0.16
  14. Marc Peeters · 1 shared paper, 2022 · strength 0.16
  15. Rekin’s Janky · 2 shared papers, 2016–2020 · strength 0.16
  16. Jos F. van Pelt · 2 shared papers, 2011–2020 · strength 0.13
  17. Hugo E J Vankelecom · 3 shared papers, 2012–2013 · strength 0.12
  18. Massimiliano Mazzone · 1 shared paper, 2022 · strength 0.11
  19. Stephan J. Reshkin · 1 shared paper, 2022 · strength 0.11
  20. Federica Cappellesso · 1 shared paper, 2022 · strength 0.11
  21. Ashenafi Shiferaw Bulle · 1 shared paper, 2020 · strength 0.10
  22. Chris Verslype · 1 shared paper, 2020 · strength 0.10
  23. Gregory Sergeant · 2 shared papers, 2011–2012 · strength 0.07
  24. Geert Roeyen · 1 shared trial, 2009 · strength 0.03
  25. Tom Feryn · 1 shared trial, 2009 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.